癌变
免疫系统
渗透(HVAC)
腺癌
癌症研究
肺
细胞
肺腺癌
生物
免疫学
医学
病理
内科学
癌症
遗传学
物理
热力学
作者
Yanjun Li,Wenke Yang,Chaojun Liu,Shengli Zhou,Xiaozhuan Liu,Tingting Zhang,Lingzhi Wu,Xiaoming Li,Jiayang Zhang,Enqiang Chang
标识
DOI:10.1016/j.intimp.2024.111918
摘要
Sideroflexin 1 (SFXN1), a mitochondrial serine transporter implicated in one-carbon metabolism, is a prognostic biomarker in lung adenocarcinoma (LUAD). However, its role in LUAD progression remains elusive. This study aimed to investigate the functional significance of SFXN1 in LUAD and evaluate its potential as a therapeutic target. We analyzed SFXN1 expression and its diagnostic and prognostic value in LUAD using the Pan-cancer TCGA dataset. In vitro assays (CCK-8, cell cycle, EDU, wound-healing, and transwell) were employed to assess the role of SFXN1, complemented by in vivo experiments. RNA sequencing elucidated SFXN1-mediated cellular functions and potential mechanisms. Bulk RNA-seq and scRNA-seq data from TCGA and GEO were used to investigate the correlation between SFXN1 and the tumor immune microenvironment. RT-qPCR, Western blot, and IHC assays validated SFXN1 expression and its impact on the immune microenvironment in LUAD. SFXN1 was upregulated in LUAD tissues and associated with poor prognosis. RNA-seq and scRNA-seq analyses revealed increased SFXN1 expression in tumor cells, accompanied by decreased infiltration of NK and cytotoxic T cells. SFXN1 knockdown significantly reduced cell proliferation and migration, and the inhibition of ERK phosphorylation and CCL20 expression may be the molecular mechanism involved. In vivo, targeting SFXN1 decreased Tregs infiltration and inhibited tumor growth. Our findings suggest that SFXN1 may be a potential therapeutic target for LUAD treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI